Patent registered at Korea Intellectual Property Office regarding IL-2v based multi-specific fusion protein
- Date2024-04-16
- View1638
Mustbio registered a patent for the MB5029, a multi-specific IL-2v immuno-oncology new drug candidate, with the Korean Intellectual Property Office. This patent pertains to a PD-1 x IL-2v bispecific fusion protein.
%EC%99%B8%EA%B5%AD%EC%96%B4%EB%93%B1%EB%A1%9D%EC%A6%9D_%ED%8E%98%EC%9D%B4%EC%A7%80_1_d908a.jpg "%ED%8A%B9%ED%97%88%EC%A6%9D_IL2%20%EB%B3%80%EC%9D%B4%EC%B2%B4%20%EB%B0%8F%20%EC%9D%B4%EB%A5%BC%20%ED%8F%AC%ED%95%A8%ED%95%98%EB%8A%94%20%EB%8B%A8%EB%B0%B1%EC%A7%88%20%EB%B3%B5%ED%95%A9%EC%B2%B4%20(%EC%A0%9C10-2655850%ED%98%B8)%EC%99%B8%EA%B5%AD%EC%96%B4%EB%93%B1%EB%A1%9D%EC%A6%9D_%ED%8E%98%EC%9D%B4%EC%A7%80_1_d908a.jpg")
